CN Patent

CN101636200A — 用于治疗庞贝氏症的方法

Assigned to Baomarui Pharmaceutical Co Ltd · Expires 2010-01-27 · 16y expired

What this patent protects

本发明提供了用于通过向主体给予治疗有效量的一种融合蛋白来治疗该主体的庞贝氏症的方法，其中该融合蛋白包含人酸性α－葡糖苷酶(GAA)或其片段，以及溶酶体靶向结构域。该溶酶体靶向结构域以非甘露糖－6－磷酸依赖型方式结合人非阳离子依赖型甘露糖－6－磷酸受体。

USPTO Abstract

本发明提供了用于通过向主体给予治疗有效量的一种融合蛋白来治疗该主体的庞贝氏症的方法，其中该融合蛋白包含人酸性α－葡糖苷酶(GAA)或其片段，以及溶酶体靶向结构域。该溶酶体靶向结构域以非甘露糖－6－磷酸依赖型方式结合人非阳离子依赖型甘露糖－6－磷酸受体。

Drugs covered by this patent

Patent Metadata

Patent number
CN101636200A
Jurisdiction
CN
Classification
—
Expires
2010-01-27
Drug substance claim
No
Drug product claim
No
Assignee
Baomarui Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.